Semax Changes Brain Network Activity Within Minutes of Nasal Administration — an fMRI Study

Intranasal Semax (1%) produced a measurable increase in the volume of the default mode network's rostral subcomponent (medial frontal cortex) compared to placebo, as detected by resting state fMRI. This effect was visible within 5 to 20 minutes of nasal administration. The finding confirms that Semax reaches the brain and alters neural network activity in a specific, topographically defined manner.

Placebo-controlled study in 24 healthy volunteers (11 men, 13 women, mean age 43.9 years). Resting state fMRI was performed three times: immediately before, 5 minutes after, and 20 minutes after intranasal administration of 1% Semax (n=14) or placebo (n=10). The default mode network was identified and its subcomponent topography analyzed.

This is one of the few human neuroimaging studies showing a peptide nootropic producing measurable changes in brain network activity. The default mode network is involved in self-referential thinking, mind-wandering, and memory consolidation. Showing that Semax specifically affects the medial frontal cortex component — associated with social cognition and emotional processing — provides neurobiological evidence for its reported cognitive and mood effects.

Peptide nootropics like Semax and Selank are widely used in Russia but have very limited neuroimaging data in humans. This study provides objective evidence that Semax crosses from the nose to the brain and produces detectable changes in neural network activity within minutes. However, it doesn't prove cognitive enhancement — seeing a brain change on fMRI and demonstrating that the change improves thinking are different things. The default mode network has been implicated in creativity, memory consolidation, and social cognition, but the functional meaning of expanding its frontal component remains to be determined.

Very small sample size (14 Semax vs. 10 placebo) limits statistical power and generalizability. The study only measured network volume changes, not cognitive or behavioral outcomes — so the functional significance of the DMN change is unknown. Only two post-administration time points were measured (5 and 20 minutes), missing later effects. No blinding verification was reported. The study was conducted by researchers associated with Semax's development institute.